Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049114 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00049114: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00049114 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049114, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining tipifarnib with doxorubicin and cyclophosphamide may kill more tumor cells. Phase II trial to study the effectiveness of combining tipifarnib with doxorubicin and cyclophosphamide in treating women who have locally advanced breast cancer.
Interventions
- DRUG cyclophosphamide
- PROCEDURE therapeutic conventional surgery
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049114
The ClinicalTrials.gov registry entry for NCT00049114 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00049114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049114 about?
NCT00049114 is a clinical study titled "Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer". Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining tipifarnib with doxorubicin and cycl...
What is the current status of trial NCT00049114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2003-02.
What interventions are being tested in trial NCT00049114?
The interventions under investigation include: cyclophosphamide (DRUG), therapeutic conventional surgery (PROCEDURE), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00049114?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.